

# CONTENTS

|  | <i>Page</i> |
|--|-------------|
| <b>Part one. General information</b> .....   | 1           |
| Notes .....  | 2           |
| Introduction .....   | 3           |
| Remarks on the statistical tables .....  | 3           |
| English-French-Spanish index of names of countries and non-metropolitan territories .....  | 9           |
| English-French-Spanish index of names of narcotic drugs .....  | 15          |
| <b>Part two. Comments on the reported statistics on narcotic drugs</b> .....   | 19          |
| Notes .....  | 20          |
| Comments on the reported statistics on narcotic drugs .....  | 21          |
| <b>Part three. Supply of opiate raw materials and demand for opiates for medical and scientific purposes</b> .....   | 111         |
| Notes .....  | 112         |
| Supply of opiate raw materials and demand for opiates for medical and scientific purposes .....  | 113         |
| <b>Part four. Statistical information on narcotic drugs</b> .....  | 143         |
| Notes .....  | 144         |
| Tables of reported statistics .....  | 145         |
| Table I. Cultivation of <i>Papaver somniferum</i> for the production of opium, 2013–2019 .....   | 157         |
| Table II. Cultivation of <i>Papaver somniferum</i> for purposes other than the production of opium, 2013–2019 .....  | 158         |
| Table III. Extraction of alkaloids from opium, 2013–2017 .....   | 164         |
| Table IV. Extraction of morphine from poppy straw (M), 2013–2017 .....   | 166         |
| Table V. Extraction of thebaine from poppy straw (T and M), 2013–2017 .....  | 170         |
| Table VI. Conversion of morphine, 2013–2017 .....  | 172         |
| Table VII. Conversion of thebaine, 2013–2017 .....   | 176         |
| Table VIII. Manufacture of alkaloids contained in concentrate of poppy straw, 2013–2017 .....  | 180         |
| Table IX. Manufacture of the principal narcotic drugs, 2013–2017 .....   | 182         |
| Table X. Manufacture of other narcotic drugs, 2013–2017 .....  | 187         |
| 1. Derivatives of opium alkaloids .....  | 187         |
| 2. Synthetic opioids .....   | 187         |
| Table XI. Production, utilization, imports and exports of coca leaf and manufacture of cocaine, 2013–2017 .....  | 188         |
| Table XII. Consumption of the principal narcotic drugs and calculated consumption of buprenorphine, 2013–2017 .....  | 190         |
| Table XIII. Consumption of other narcotic drugs, 2013–2017 .....   | 218         |
| 1. Fentanyl, principal fentanyl analogues and piritramide .....  | 218         |
| 2. Other derivatives of opium alkaloids .....  | 239         |
| 3. Other synthetic opioids .....   | 239         |
| Table XIV. Levels of consumption of narcotic drugs, in defined daily doses for statistical purposes per million inhabitants per day, 2015–2017 .....   | 240         |
| 1. Average consumption of narcotic drugs (excluding preparations in Schedule III) and calculated consumption of buprenorphine .....  | 240         |
| a. All countries .....   | 240         |
| b. Africa .....  | 248         |
| c. Asia .....  | 250         |
| d. Central America and the Caribbean .....   | 253         |
| e. Europe .....  | 255         |
| f. North America .....   | 257         |
| g. Oceania .....   | 258         |
| h. South America .....   | 260         |
| i. All regions .....   | 261         |
| 2. Global average levels of utilization of narcotic drugs for the manufacture of preparations listed in Schedule III, in defined daily doses for statistical purposes per million inhabitants per day, 2008–2017 ..... | 262         |
| 3. Global consumption of opioids, expressed in millions of defined daily doses for statistical purposes (S-DDD) 1998–2017 ..   | 263         |
| Table XV. Total stocks of narcotic drugs, 2013–2017 .....  | 265         |

**Annexes\***

|   |     |
|---|-----|
| I. Status of adherence to international conventions on narcotic drugs and receipt of statistics (2017) and estimates (2019) . . . . . | 269 |
| Notes . . . . .   | 270 |
| Table . . . . .   | 271 |
| II. Estimated requirements of narcotic drugs . . . . .  | 281 |
| Notes . . . . .   | 282 |
| Table A. Estimated world requirements of narcotic drugs for 2019 . . . . .  | 284 |
| Table B. World totals of estimates, 2014–2019 . . . . .   | 322 |
| III. Comparative statement of estimates and statistics for 2017 . . . . .   | 325 |
| Notes . . . . .   | 326 |
| Table . . . . .   | 328 |
| IV. World trade, 2015–2017 . . . . .  | 429 |
| Notes . . . . .   | 430 |
| 1. Exports of opiate raw materials, 2015–2017 . . . . .   | 431 |
| 2. Imports of opiate raw materials, 2015–2017 . . . . .   | 433 |
| 3. Exports of the principal narcotic drugs, 2015–2017 . . . . .   | 436 |
| 4. Imports of the principal narcotic drugs, 2015–2017 . . . . .   | 446 |
| V. Seizures of selected narcotic drugs, 2017 . . . . .  | 467 |
| Notes . . . . .   | 468 |
| Table . . . . .   | 469 |

---

\*As of 2018, the CD-Rom is no longer included in the printed version of this report. The report in its entirety, including the annexes, are available on the INCB website ([www.incb.org](http://www.incb.org)).